Phase 2 Leukemia clinical trials

92 recruiting Phase 2 leukemia studies in the US. What trial phases mean

Other phases

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Anchorage, AK · Mesa, AZ · +112 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Tucson, AZ · +172 more sites

RecruitingPhase 2NCT06128070

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Sponsor: City of Hope Medical Center

Duarte, CA

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Tucson, AZ · +222 more sites

RecruitingPhase 2NCT06236724

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Tucson, AZ · Little Rock, AR · +132 more sites

RecruitingPhase 2NCT07269470

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT06315309

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

Sponsor: University of Alabama at Birmingham

Birmingham, AL

RecruitingPhase 2NCT00501826

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT05672251

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Sponsor: City of Hope Medical Center

Duarte, CA

RecruitingPhase 2NCT07060001

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Sponsor: The Methodist Hospital Research Institute

Houston, TX

RecruitingPhase 2NCT00801489

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT07605416

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Sponsor: National Cancer Institute (NCI)

New Haven, CT · North Haven, CT · Baton Rouge, LA · +7 more sites

RecruitingPhase 2NCT06811233

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT07061951

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Sponsor: National Cancer Institute (NCI)

Duarte, CA · Irvine, CA · Sacramento, CA · +6 more sites

RecruitingPhase 2NCT03586609

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT06707493

Ivosidenib as Post-HSCT Maintenance for AML

Sponsor: Massachusetts General Hospital

Atlanta, GA · Kansas City, KS · Boston, MA · +4 more sites

RecruitingPhase 2NCT06863402

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Sponsor: Roswell Park Cancer Institute

Buffalo, NY

RecruitingPhase 2NCT07304011

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

Sponsor: University of California, Davis

Orange, CA · Sacramento, CA

RecruitingPhase 2NCT03516617

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Sponsor: Mayo Clinic

Scottsdale, AZ · Jacksonville, FL · Rochester, MN

RecruitingPhase 2NCT05592015

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Sponsor: Jonathan Brammer

Boston, MA · New York, NY · Columbus, OH

RecruitingPhase 2NCT06817720

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT06514794

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Sponsor: Allotera Therapeutics

Duarte, CA · Los Angeles, CA · Denver, CO · +13 more sites

RecruitingPhase 2NCT03629171

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT06144606

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Tampa, FL

RecruitingPhase 2NCT03986034

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Bethesda, MD

RecruitingPhase 2NCT07710534

Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

Sponsor: Virginia Commonwealth University

Richmond, VA

RecruitingPhase 2NCT07221500

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Sponsor: Nurix Therapeutics, Inc.

Phoenix, AZ · Duarte, CA · Los Angeles, CA · +24 more sites

RecruitingPhase 2NCT06504459

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Sponsor: OHSU Knight Cancer Institute

Miami, FL · Portland, OR

RecruitingPhase 2NCT06824168

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Sponsor: Daiichi Sankyo

Birmingham, AL · Los Angeles, CA · Baltimore, MD · +12 more sites

RecruitingPhase 2NCT04996875

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Sponsor: Cogent Biosciences, Inc.

Birmingham, AL · Phoenix, AZ · Duarte, CA · +11 more sites

RecruitingPhase 2NCT06904482

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

Sponsor: Case Comprehensive Cancer Center

Cleveland, OH

RecruitingPhase 2NCT03683433

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT04216524

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT06566742

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

Sponsor: M.D. Anderson Cancer Center

Miami, FL · Houston, TX

RecruitingPhase 2NCT07194980

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase 2NCT04169737

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT07734038

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Sponsor: Kerry Rogers

Columbus, OH

RecruitingPhase 2NCT06930352

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Sponsor: Uma Borate

Columbus, OH

RecruitingPhase 2NCT04493164

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT07227584

ALL Backbone in AYAs

Sponsor: Dana-Farber Cancer Institute

Boston, MA

RecruitingPhase 2NCT03737955

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Sponsor: University of Washington

Seattle, WA

RecruitingPhase 2NCT07224100

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Sponsor: University of Washington

Seattle, WA

RecruitingPhase 2NCT03136146

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT06967610

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT06013423

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase 2NCT07046078

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase 2NCT05805605

Allo HSCT Using RIC and PTCy for Hematological Diseases

Sponsor: Masonic Cancer Center, University of Minnesota

Minneapolis, MN

RecruitingPhase 2NCT03314974

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Sponsor: Masonic Cancer Center, University of Minnesota

Minneapolis, MN

RecruitingPhase 2NCT05365035

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Sponsor: M.D. Anderson Cancer Center

Houston, TX

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.